Measuring and Improving Quality Care in Rheumatoid Arthritis

Measuring and Improving Quality Care in Rheumatoid Arthritis

UM Logo undefined

CREDITS

20 AMA PRA CATEGORY I CREDITS ™ (no partial credit are awarded).

Estimated Time to Complete CME Activity

3-5 months

ACCREDITATION STATEMENT

The University of Miami Leonard M. Miller School of Medicine is accredited by the Accreditation Council (ACCME) for Continuing Medical Education to provide continuing medical education for physicians.

This activity was planned and produced in accordance to ACCME Essentials.

The University of Miami Leonard M. Miller School of Medicine designates this performance improvement CME (PI CME) activity for a maximum of 20 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

LEARNING OBJECTIVES

Upon completion of this educational activity, learners will be able to:

  • Recognize the role of measurement of and/or improvement in quality care in rheumatoid arthritis (RA) management
  • Describe the RA quality indicators endorsed by the American College of Rheumatology (ACR) and the related quality indicators endorsed by the CMS PQRS program
  • Recognize the importance of employing a treat-to-target approach involving early and optimal use of traditional and biologic disease modifying antirheumatic drugs (DMARDs) together with regular monitoring of RA disease activity using standardized disease activity measures
  • Develop and implement a performance improvement plan to overcome barriers to the optimal management of RA in clinical practice

TARGET AUDIENCE

This CME activity is intended for Rheumatologists and other physicians that care for patients with Rheumatoid Arthritis.

STATEMENT OF INDEPENDENCE

As a provider of continuing medical education (CME) accredited by the Accreditation Council for Continuing Medical Education, the University of Miami Leonard M. Miller School of Medicine has a policy of ensuring that the content and quality of this educational activity is balanced, independent, objective, and scientifically rigorous. The structure and content of the PIM was developed under the supervision of the University of Miami Leonard M. Miller School of Medicine in coprovidership with the National Association for Continuing Education and the PIM faculty.

Faculty and Planning Committee

Course Director
Carlos J. Lozada, MD
Professor of Clinical Medicine
Director, Rheumatology Fellowship Program
University of Miami Miller School of Medicine
University of Miami/Jackson Memorial Medical Center
Miami, FL

Faculty
Charles King, MD
Senior Clinical Rheumatologist
North Mississippi Health Services
Tupelo, MS
Associate Professor of Medicine
University of Tennessee-Memphis Health Sciences Center
Memphis, TN

Kenneth G. Saag, MD, MSc
Jane Knight Lowe Professor
Director, Center for Education and Research on Therapeutics (CERTs)
Center for Outcomes Effectiveness and Education (COERE)
Center of Research Translation (CORT) in Gout and Hyperuricemia
Department of Medicine
Division of Clinical Immunology and Rheumatology
The University of Alabama at Birmingham
Birmingham, AL

Ozlem Pala, MD
Assistant Professor of Clinical Medicine
University of Miami Miller School of Medicine
Division of Rheumatology & Immunology
Miami, FL

Planning Committee
Michelle Frisch, MPH, CCMEP
National Association For Continuing Education
Plantation, FL

Cheryl C. Kay
National Association For Continuing Education
Plantation, FL

Harvey C. Parker, PhD, CCMEP
National Association For Continuing Education
Plantation, FL

Oscar Reyes
Director
Division of Continuing Medical Education
University of Miami Miller School of Medicine
Miami, FL

Stephen Webber
National Association For Continuing Education
Plantation, FL

Medical Writer
Joshua Kilbridge
President
Kilbridge Associates
San Francisco, CA

DISCLOSURE POLICY

It is the policy of the University of Miami Leonard M. Miller School of Medicine to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Miami Leonard M. Miller School of Medicine are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. The University of Miami Leonard M. Miller School of Medicine has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable. Faculty disclosures are provided below.

Carlos Lozada, MD, Course Director, has the following relationship to disclose: Consultant: Pfizer.

Charles King, MD, Faculty, has the following relationships to disclose: Consultant/Researcher: Amgen, Merck and Anadys; Consultant: Abbott and AbbVie; Researcher: Takeda.

Kenneth G Saag, MD, MSc, Faculty, has no relationships to disclose.

Ozlem Pala, MD, Faculty, has no relationships to disclose.

Michelle Frisch, MPH, CCMEP, Planning Committee, has no relationships to disclose.

Cheryl C. Kay, Planning Committee, has no relationships to disclose.

Josh Kilbridge, Medical Writer, has no relationships to disclose.

Harvey C. Parker, PhD, CCMEP, Planning Committee, has no relationships to disclose.

Oscar Reyes, Planning Committee, has no relationships to disclose.

Stephen Webber, Planning Committee, has no relationships to disclose.

DISCLAIMERS

Use of professional judgment:
The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.

Drugs and dosages:
When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.

POLICY ON UNLABELED/OFF-LABEL USE

The University of Miami Leonard M. Miller School of Medicine has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). University of Miami Leonard M. Miller School of Medicine requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

PRIVACY AND CONFIDENTIALITY STATEMENT

The University of Miami Leonard M. Miller School of Medicine will record learner’s personal information to track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.

The University of Miami Leonard M. Miller School of Medicine takes the protection of your patients’ privacy very seriously. To that end, the Society collects only the minimum amount of patient-level data necessary and has implemented HIPAA-compliant administrative, physical, and technical controls to protect the patient-level data both in transit and at rest. To further protect patient anonymity, learners should not enter a patient’s name (full or partial) or SSN in the Patient ID field.

ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT

This activity is supported by an independent medical education grant from Pfizer.

METHOD OF PARTICIPATION

This PI activity is presented online. The estimated time in which a learner will be actively engaging with this online module is 20 hours. Please note that due to the design of the PIM experience, learners should anticipate engaging in this activity over a period of time during which improvements can be planned and implemented. For example, after the initial baseline measurement, the learner will be asked to develop an improvement plan. The learner should anticipate the appropriate amount of time to implement the improvement plan and generate 10 new patient charts for the second and third improvement cycles.

SYSTEM REQUIREMENTS

To complete this activity, participants must: have access to a computer with an Internet connection; use a major web browser, such as Internet Explorer 7+, Firefox 2+, Safari, Opera, or Google Chrome; and cookies and Javascript must be enabled in the browser’s options.

ACTIVITY RELEASE DATE:

January 7, 2015

ACTIVITY EXPIRATION DATE:

January 6, 2016 (date after which this PI CME activity is no longer certified for AMA PRA Category 1 Credits™).

For assistance or information, please contact contact@healthmonix.com.

ADDITIONAL INFORMATION

In addition, this program provides submission of your data to CMS to fulfill the requirements of the PQRS program.
Free PQRS Submission for the first 50 physicians that complete by March 1, 2015.

This program is available to you at no charge.

Click here to Register

UM Logo undefined